Haleon PLC
Company Profile
Business description
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon’s brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Contact
The Heights
Building 5, First Floor
Surrey
WeybridgeKT13 0NY
GBRT: +44 1932959500
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
24,622
Stocks News & Analysis
stocks
Expense concerns for ASX best idea
stocks
Chart of the Week: Australian asset managers face structural pressure
stocks
Going into earnings, is Alphabet a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,204.30 | 39.00 | -0.42% |
| CAC 40 | 8,066.68 | 86.14 | -1.06% |
| DAX 40 | 24,822.79 | 71.65 | -0.29% |
| Dow JONES (US) | 49,015.60 | 12.19 | 0.02% |
| FTSE 100 | 10,154.43 | 53.37 | -0.52% |
| HKSE | 27,975.81 | 148.90 | 0.54% |
| NASDAQ | 23,857.45 | 40.35 | 0.17% |
| Nikkei 225 | 53,455.07 | 96.36 | 0.18% |
| NZX 50 Index | 13,348.61 | 64.26 | -0.48% |
| S&P 500 | 6,978.03 | 0.57 | -0.01% |
| S&P/ASX 200 | 8,897.80 | 25.40 | -0.28% |
| SSE Composite Index | 4,147.15 | 4.08 | -0.10% |